SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Sep 21, 2026	Sep 21, 2026	View filing
8-K	Aug 31, 2026	Aug 31, 2026	View filing
4	Aug 20, 2026	Aug 20, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
SC 13D/A	Aug 17, 2026	Aug 17, 2026	View filing
8-K	Aug 17, 2026	Aug 17, 2026	View filing
424B7	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 10, 2026	Aug 10, 2026	View filing
8-K	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 3, 2026	Aug 3, 2026	View filing
SC 13G/A	Aug 3, 2026	Aug 3, 2026	View filing
SC 13G/A	Jul 27, 2026	Jul 27, 2026	View filing
S-3ASR	Jul 24, 2026	Jul 24, 2026	View filing
S-8	Jul 24, 2026	Jul 24, 2026	View filing
8-K	Jul 22, 2026	Jul 22, 2026	View filing
4	Jul 13, 2026	Jul 13, 2026	View filing
4	Jul 13, 2026	Jul 13, 2026	View filing
SC 13D/A	Jul 10, 2026	Jul 10, 2026	View filing
8-K	Jul 2, 2026	Jul 2, 2026	View filing
8-K	Jun 26, 2026	Jun 26, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Palo Alto, CA

999 employees

www.bridgebio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Neil Kumar

View full financials